rMVA SARS-CoV-2 Vaccine Composition for Variant Immune Escape

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccines against SARS-CoV2 are challenged by high mutation rates and potential immune escape, necessitating the development of vaccines that provide broad immunity to various SARS-CoV2 variants.

Innovation Solution

Recombinant modified vaccinia Ankara (rMVA) viral vectors expressing multiple SARS-CoV2 antigens, such as Spike, Membrane, and Envelope proteins, form virus-like particles (VLPs) to induce robust humoral and cellular immune responses, including variants with mutations like K417T, E484K, and N501Y.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current vaccines are used against SARS-CoV2, then immunity is provided to some extent, but high mutation rates and potential immune escape reduce effectiveness

Engineering Contradiction:

Improvevaccine effectivenessVSAvoidprotection against variants

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The vaccine divides the SARS-CoV2 antigens into multiple separate components (Spike protein, Membrane protein, Envelope protein) and presents them through different viral vectors (MVA, NYVAC, FC122). This segmentation ensures that even if the virus mutates in one antigenic region, the immune system has been exposed to multiple distinct antigenic targets, reducing the likelihood of complete immune escape.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The vaccine system uses multiple viral vectors (MVA, NYVAC, FC122) that can each independently deliver SARS-CoV2 antigens. These vectors have different replication properties and immune stimulation capabilities, making the system universally effective across different variants. The multi-functional approach ensures broad protection against various SARS-CoV2 strains including potential future variants.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Adaptability or versatility

If multiple SARS-CoV2 antigens are expressed to broaden immunity, then protection against variants improves, but vaccine complexity increases

Engineering Contradiction:

Improveprotection against variantsVSAvoidvaccine composition

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The vaccine merges multiple SARS-CoV2 antigens (Spike, Membrane, Envelope proteins) into a single composite vaccine formulation. Rather than administering separate vaccines for each antigen, they are combined in one injection, simplifying the administration process while maintaining broad protective immunity against multiple variants.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent uses viral vectors (MVA, NYVAC, FC122) as intermediary carriers to deliver multiple SARS-CoV2 antigens simultaneously. These viral vectors act as mediators that package and deliver multiple antigenic components into host cells, simplifying the delivery mechanism while enabling broad antigen presentation to the immune system.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12577589B2Vaccines and uses thereof to induce an immune response to SARS-CoV2

Publication Date: 2026.03.17 GEOVAX INC

AI summary

Provided herein are recombinant modified vaccinia Ankara (rMVA) viral vectors comprising heterologous nucleic acid inserts encoding one or more SARS-CoV2 proteins, peptides, or fragments thereof, operably linked to a promoter compatible with poxvirus expression systems that, upon expression, are capable of inducing protective immunity. The compositions can be used in a priming vaccination strategy or in a prime/boost vaccination strategy to provide immunity to SARS-CoV2 and variants thereof.